



## FUNDAMENTALLY IMPROVING THE LIVES OF PEOPLE WITH SEVERE ASTHMA

### GLOBAL NARRATIVE


Asthma is one of the most common chronic lung diseases worldwide<sup>1</sup> affecting 339 million people and representing a significant health problem globally, including in many less developed countries where it is often under-diagnosed and under-treated.<sup>2</sup>

Asthma is a chronic inflammatory disease of the airways of the lung. This inflammation can lead to a range of symptoms, as well as acute episodes of constriction of the airways, known as 'attacks'.<sup>3</sup>

All patients with asthma are at risk of an asthma attack, which, in combination with the long-term effects of the disease itself can impact a patient's ability to work or go to school, to maintain relationships and to live an independent life.<sup>4,5</sup>

Severe asthma, which is estimated to affect up to 10% of the asthma population<sup>6</sup>, is highly debilitating and potentially fatal. Patients can experience frequent, severe attacks, have significant limitations in their lung function and have a poor quality of life.<sup>7,8</sup>

### A CHALLENGING SEVERE ASTHMA SCENARIO



### PRECISION WILL IMPACT THE LIVES OF PATIENTS LIVING WITH SEVERE ASTHMA

PRECISION is a multi-disciplinary programme organised and funded by AstraZeneca to fundamentally improve the lives of people living with severe asthma by creating an environment where patients routinely receive the right care at the right time in the most appropriate setting.

Through PRECISION, we are working with global and national respiratory experts from clinical practice, patient advocacy groups and the payer and policy community, to accelerate appropriate patient referrals, build clinical capabilities, expand system capacity and evolve healthcare policies.





# PRECISION

## PRECISION PROGRAMME PILLARS



### ACCELERATE APPROPRIATE REFERRALS

Support healthcare networks to ensure timely and appropriate referral of patients suspected of having severe asthma, from primary care to specialists. Educate referring HCPs in the management of severe asthma, support stronger referral networks, achieve consensus on clear referral criteria, and work with professionals to implement efficiencies across the patient pathway.



### BUILD CAPABILITY

Support specialists to diagnose accurately and treat patients with severe asthma effectively through impactful education around the diagnosis and treatment of severe asthma.



### EXPAND CAPACITY

Support health system infrastructure to increase timely management and treatment of patients with severe asthma. Experts will map current service provision and patient experience, supporting new services to improve efficiency in severe asthma centres and explore new ways to meet patient demand.



### IMPROVE ACCESS

Work with advocates across the severe asthma community to ensure patients have access to appropriate care, with the support of policy and payers. This will be achieved by building international consensus on the care that patients should expect, auditing services to identify the gaps in quality and access, and putting policy and system improvements in place to address these.

## What will PRECISION do?

AstraZeneca is committed to the scientific discovery and the development of new treatments which can improve the lives of people living with severe asthma. However, treatment is only one part of that story. PRECISION represents AstraZeneca's broader commitment to ensuring that severe asthma patients can realise better outcomes and experiences through improving the design and delivery of severe asthma care.

**BY 2021, PRECISION WILL IMPROVE THE PATIENT JOURNEY FOR PEOPLE LIVING WITH SEVERE ASTHMA. PRECISION WILL DELIVER NEW OR UPDATED NATIONAL QUALITY STANDARDS FOR SEVERE ASTHMA, WITH A FOCUS ON FASTER PATIENT JOURNEYS AND BETTER CARE.**

#### References

1. World Health Organization. Asthma Fact Sheet. 2017. Available online via: [www.who.int/features/factfiles/asthma/en/](http://www.who.int/features/factfiles/asthma/en/) [last accessed 15.08.18].
2. The Global Asthma Network. The Global Asthma Report 2018. Available from: <http://globalasthmareport.org/Global%20Asthma%20Report%202018.pdf> [last accessed 15.08.18]
3. Health and Safety Executive. Your Lungs – an asthma attack. Available from: [www.hse.gov.uk/asthma/lungs.htm](http://www.hse.gov.uk/asthma/lungs.htm) [last accessed 15.08.18]
4. Braido F. Failure in Asthma Control: Reasons and Consequences. *Scientifica* 2013; 2013:549252.
5. Dusser D, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. *Allergy* 2007; 62: 591–604
6. Canonica GW, et al. Therapeutic interventions in severe asthma. *World Allergy Organization Journal* 2016; 9: 40
7. Foster JM, et al. "I have lost in every facet of my life": the hidden burden of severe asthma. *Eur Respir J* 2017 50: 1700765
8. Asthma UK. Severe Asthma: The unmet need and the global challenge. 2018. Available from: [https://www.asthma.org.uk/globalassets/get-involved/external-affairs-campaigns/publications/severe-asthma-report/auk\\_severeasthma\\_2017.pdf](https://www.asthma.org.uk/globalassets/get-involved/external-affairs-campaigns/publications/severe-asthma-report/auk_severeasthma_2017.pdf) [last accessed 09.08.18]
9. The Global Asthma Network. The Global Asthma Report 2018. [Online]. Available at: [http://www.globalasthmanetwork.org/publications/Global\\_Asthma\\_Report\\_2018.pdf](http://www.globalasthmanetwork.org/publications/Global_Asthma_Report_2018.pdf) [Last accessed 7 September 2018]
10. Wenzel S. Severe Asthma in Adults. *Am J Respir Crit Care Med*. 2005;172: 149-160